Skip to main content

Alterations in T Cell Subpopulations Linked to Brain Structure in Tardive Dyskinesia

Medically reviewed by Carmen Pope, BPharm. Last updated on July 25, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, July 25, 2024 -- Alterations in the proportion of T cell subpopulations are associated with brain structural abnormalities in patents with schizophrenia with tardive dyskinesia (TD), according to a study published in the July issue of Schizophrenia Research.

Na Li, from the Peking University HuiLongGuan Clinical Medical School in Beijing, and colleagues examined the correlations between distributions of T cell phenotypes and brain structure abnormalities in 50 schizophrenia patients with TD (TD) and 58 without TD (NTD), relative to 41 healthy controls (HC). Naive (CD45RA+), memory (CD45RO+), and apoptotic (CD95+) CD4+ and CD8+ T cells were examined by flow cytometry, as were the intracellular levels of cytokines in CD8+CD45RA+CD95+ and CD8+CD45RO+CD95+ T cells.

The researchers found that compared to the NTD and HC groups, the TD group had a higher percentage of CD8+CD45RO+CD95+ T cells, which correlated with the choroid plexus volume in the TD group. Associations were seen for the intracellular level of interferon-γ in CD8+CD45RO+CD95+ T cells, the fractional anisotropy (FA) of the fornix/stria terminalis, and the pallidum volume with orofacial TD, while correlations were seen for the fractional anisotropies of the inferior fronto-occipital fasciculus, cingulum, and superior longitudinal fasciculus with limb-truncal TD.

"These findings provide preliminary evidence that the association between immunosenescence-related T cell subpopulations and brain structure may underline the pathological process of TD," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted July 2024

Read this next

Risk for Schizophrenia Increased With ED Visits Involving Hallucinogen Use

THURSDAY, Nov. 21, 2024 -- In individuals without a history of psychosis, the risk for developing a schizophrenia spectrum disorder (SSD) is increased for individuals with an...

Transcranial Direct Current Stimulation Safe, Effective for Tardive Dyskinesia

MONDAY, Nov. 18, 2024 -- Transcranial direct current stimulation (tDCS) may be an effective and safe treatment for improving the facial-oral motor symptoms of tardive dyskinesia...

FDA Approves Cobenfy for Adults With Schizophrenia

THURSDAY, Nov. 14, 2024 -- The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.